Citi Lowers SINOPHARM (01099.HK) Price Target to $22.7, Maintains Buy Rating
Company Outlook: SINOPHARM's management remains optimistic about long-term industry growth despite short-term pressures from regional healthcare funding and volume-based procurement challenges.
Government Support: Starting from 2Q25, there is expected to be increased government support for innovative drugs and medical devices, leading to significant revenue and gross profit growth.
Sales Growth: Professional pharmacies reported a year-on-year sales increase of 13-14% in the first half of 2025, attributed to the rapid growth of innovative drugs.
Revised Forecasts: Citi Research has adjusted its revenue and net profit forecasts for SINOPHARM downwards for 2025-2027 and lowered the target price from $23.8 to $22.7 while maintaining a "Buy" rating.
Trade with 70% Backtested Accuracy
Analyst Views on 01099
About the author
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
Sinopharm Accord, a Subsidiary of SINOPHARM, Projects Up to 90% Increase in Last Year's Net Profit
Company Overview: Sinopharm Accord, a subsidiary of SINOPHARM, is experiencing significant growth, with a projected YoY increase in net profit attributable to shareholders for 2025 estimated between 64.20% and 89.11%.
Profit Expectations: The company's net profit, excluding non-recurring gains and losses, is expected to rise by approximately 71.38% to 98.91% YoY, reaching between RMB996 million and RMB1.156 billion.
Earnings Per Share: Basic earnings per share are anticipated to increase to around RMB1.9-2.18, compared to RMB1.15 in the previous year.
Market Activity: The stock has seen short selling activity amounting to $20.10 million, with a short selling ratio of 23.277%.
<Full-day Summary> HSI Falls 454 Points; HSTI Declines 111 Points; XPENG Drops More Than 10%; SHANGHAI IND H Reaches New Highs; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 454 points (1.7%) to close at 25,930, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 1.9% and 1.6%, respectively.
Active Heavyweights: Major stocks like Xiaomi, Tencent, and Meituan saw significant drops, with Xiaomi down 2.8%, Tencent down 2%, and Meituan down 1.7%, alongside notable short selling activity.
Notable Declines: XPeng's stock plummeted by 10.5%, while other companies like China Hongqiao and Zhongsheng Holding also faced substantial losses, indicating a broader trend of declining stock prices among constituents.
Short Selling Trends: A variety of stocks experienced high short selling ratios, with companies like Wharf REIC and Lenovo Group showing significant short selling activity, reflecting investor sentiment amid market volatility.
<Daily Summary> HSI Ends at 26,696, Gaining 47 Points; HSTI Finishes at 5,924, Up 8 Points; XPENG Surges Over 17%; PING AN, XPENG, CHINA RES MIXC, HSBC HOLDINGS, ABC Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) rose by 47 points (0.2%) to close at 26,696, with a total market turnover of $210.23 billion.
Active Heavyweights: Notable movements included Alibaba (BABA) down 1.8%, Xiaomi (XIAOMI) up 1.5%, and Tencent (TENCENT) slightly up by 0.1%.
Top Gainers: XPENG saw a significant increase of 17.9%, while other notable gainers included Sinopharm and China Res Mixc, both hitting new highs.
Short Selling Activity: The short selling ratios varied across stocks, with Ping An having a high ratio of 30.9% and several stocks like HSBC and ABC also reaching new highs despite short selling pressures.
Midday Update: HSI Ends at 26,595, Down 53 Points; HSTI at 5,900, Down 14 Points; XPENG Rises Over 15%; HSBC Holdings, AIA, CK Asset, ABC, and Poly Property Reach New Highs
Market Performance: The Hang Seng Index (HSI) fell by 53 points (0.2%) to 26,595, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Alibaba, Meituan, and Tencent saw declines, with Alibaba dropping 2.3% and Tencent down 0.8%, while Xiaomi gained 0.7%.
Notable Gainers: XPENG surged by 15.1%, and other stocks like Sinopharm and Baidu also posted significant gains, reflecting positive movements among certain constituents.
Short Selling Trends: High short selling ratios were observed in several stocks, with Baidu and Ping An showing notable activity, indicating investor caution in the market.
HSBC Research Lowers Price Targets for SH PHARMA and SINOPHARM; Chinese Pharmaceutical Sector Lacks Short-Term Drivers
Current State of the Chinese Pharmaceutical Industry: HSBC Global Research reports that the Chinese pharmaceutical industry lacks short-term catalysts for growth, with a weakening recovery in the domestic market and ongoing policy uncertainties.
Impact on Earnings Growth: Companies are struggling to offset slowing earnings growth, relying on operational efficiency improvements, while facing challenges from delayed domestic consumption recovery and volume-based procurement policies.
Stock Ratings and Price Adjustments: HSBC maintains a Hold rating for SH PHARMA and SINOPHARM, with SH PHARMA's target price reduced from HKD12.1 to HKD11.8, and SINOPHARM's increased from HKD18 to HKD19.5.
Short Selling Trends: The report highlights significant short selling activity in both companies, indicating market skepticism about their short-term performance, with SH PHARMA and SINOPHARM experiencing short selling ratios of 6.344% and 14.540%, respectively.
UOB Kay Hian Supports ALI HEALTH and PA GOODDOCTOR as AI Innovations and National Policies Propel China's Internet Healthcare Industry
Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.
Sinopharm Accord, a Subsidiary of SINOPHARM, Projects Up to 90% Increase in Last Year's Net Profit
Company Overview: Sinopharm Accord, a subsidiary of SINOPHARM, is experiencing significant growth, with a projected YoY increase in net profit attributable to shareholders for 2025 estimated between 64.20% and 89.11%.
Profit Expectations: The company's net profit, excluding non-recurring gains and losses, is expected to rise by approximately 71.38% to 98.91% YoY, reaching between RMB996 million and RMB1.156 billion.
Earnings Per Share: Basic earnings per share are anticipated to increase to around RMB1.9-2.18, compared to RMB1.15 in the previous year.
Market Activity: The stock has seen short selling activity amounting to $20.10 million, with a short selling ratio of 23.277%.
<Full-day Summary> HSI Falls 454 Points; HSTI Declines 111 Points; XPENG Drops More Than 10%; SHANGHAI IND H Reaches New Highs; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 454 points (1.7%) to close at 25,930, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 1.9% and 1.6%, respectively.
Active Heavyweights: Major stocks like Xiaomi, Tencent, and Meituan saw significant drops, with Xiaomi down 2.8%, Tencent down 2%, and Meituan down 1.7%, alongside notable short selling activity.
Notable Declines: XPeng's stock plummeted by 10.5%, while other companies like China Hongqiao and Zhongsheng Holding also faced substantial losses, indicating a broader trend of declining stock prices among constituents.
Short Selling Trends: A variety of stocks experienced high short selling ratios, with companies like Wharf REIC and Lenovo Group showing significant short selling activity, reflecting investor sentiment amid market volatility.
<Daily Summary> HSI Ends at 26,696, Gaining 47 Points; HSTI Finishes at 5,924, Up 8 Points; XPENG Surges Over 17%; PING AN, XPENG, CHINA RES MIXC, HSBC HOLDINGS, ABC Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) rose by 47 points (0.2%) to close at 26,696, with a total market turnover of $210.23 billion.
Active Heavyweights: Notable movements included Alibaba (BABA) down 1.8%, Xiaomi (XIAOMI) up 1.5%, and Tencent (TENCENT) slightly up by 0.1%.
Top Gainers: XPENG saw a significant increase of 17.9%, while other notable gainers included Sinopharm and China Res Mixc, both hitting new highs.
Short Selling Activity: The short selling ratios varied across stocks, with Ping An having a high ratio of 30.9% and several stocks like HSBC and ABC also reaching new highs despite short selling pressures.
Midday Update: HSI Ends at 26,595, Down 53 Points; HSTI at 5,900, Down 14 Points; XPENG Rises Over 15%; HSBC Holdings, AIA, CK Asset, ABC, and Poly Property Reach New Highs
Market Performance: The Hang Seng Index (HSI) fell by 53 points (0.2%) to 26,595, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Alibaba, Meituan, and Tencent saw declines, with Alibaba dropping 2.3% and Tencent down 0.8%, while Xiaomi gained 0.7%.
Notable Gainers: XPENG surged by 15.1%, and other stocks like Sinopharm and Baidu also posted significant gains, reflecting positive movements among certain constituents.
Short Selling Trends: High short selling ratios were observed in several stocks, with Baidu and Ping An showing notable activity, indicating investor caution in the market.
HSBC Research Lowers Price Targets for SH PHARMA and SINOPHARM; Chinese Pharmaceutical Sector Lacks Short-Term Drivers
Current State of the Chinese Pharmaceutical Industry: HSBC Global Research reports that the Chinese pharmaceutical industry lacks short-term catalysts for growth, with a weakening recovery in the domestic market and ongoing policy uncertainties.
Impact on Earnings Growth: Companies are struggling to offset slowing earnings growth, relying on operational efficiency improvements, while facing challenges from delayed domestic consumption recovery and volume-based procurement policies.
Stock Ratings and Price Adjustments: HSBC maintains a Hold rating for SH PHARMA and SINOPHARM, with SH PHARMA's target price reduced from HKD12.1 to HKD11.8, and SINOPHARM's increased from HKD18 to HKD19.5.
Short Selling Trends: The report highlights significant short selling activity in both companies, indicating market skepticism about their short-term performance, with SH PHARMA and SINOPHARM experiencing short selling ratios of 6.344% and 14.540%, respectively.
